Evidence map›Paper›PMID 33294265›Full record

ArticleAmerican journal of cancer research2020

TAS-102 has a tumoricidal activity in multiple myeloma.

Guoli Li, Huan Liu, Jin He, Zongwei Li, Zhiming Wang, Shan Zhou, Guopei Zheng, Zhimin He, Jing Yang

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 84% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Guoli LiCancer Research Institute and Cancer Hospital, Guangzhou Medical University Guangzhou, Guangdong, P. R. China.
Huan LiuDepartment of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center Houston, Texas 77030, USA.
Jin HeDepartment of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center Houston, Texas 77030, USA.
Zongwei LiDepartment of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center Houston, Texas 77030, USA.
Zhiming WangDepartment of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center Houston, Texas 77030, USA.
Shan ZhouDepartment of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center Houston, Texas 77030, USA.
Guopei ZhengCancer Research Institute and Cancer Hospital, Guangzhou Medical University Guangzhou, Guangdong, P. R. China.
Zhimin HeCancer Research Institute and Cancer Hospital, Guangzhou Medical University Guangzhou, Guangdong, P. R. China.
Jing YangDepartment of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center Houston, Texas 77030, USA.
Houston Methodist · USGuangzhou Medical University Cancer Hospital · CNThe University of Texas MD Anderson Cancer Center · US

Funding

Role of integrin VLA-6 in suppression of bone formation in myelomaR01CA193362 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI YANG, JING · 2016 to 2020
$1.8M
Targeting adipocyte-secreted chemerin for chemotherapy resistance in myelomaR01CA190863 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI YANG, JING · 2015 to 2019
$1.8M
NCI NIH HHS R01 CA190863NCI NIH HHS R01 CA193362
6 · The paper itself

Abstract

TAS-102/Lonsurf is a new oral anti-tumor drug consisting of trifluridine and tipiracil in a 1:0.5 molar ratio. Lonsurf has been approved globally, including US, Europe Union, and China, to treat patients with advanced colorectal cancer. Ongoing clinical trials are currently conducted for the treatment of other solid cancers. However, the therapeutic potential of TAS-102 in hematological malignancies has not been explored. In this study, we investigate the therapeutic efficacy of TAS-102 in multiple myeloma both

Indexed as

Multiple myelomaTAS-102therapeutic effectstipiraciltrifluridine

Identifiers

PMID33294265
PMCPMC7716153
OpenAlexW3112742238

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.